Tina Thomson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tina Thomson has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Paul Martin
Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK
4 shared publications Peter Kelleher
Department of Infection and Immunity Sciences, Northwest London Pathology NHS trust, Charing Cross Hospital, Fulham Palace Road, London W6 6RF, United Kingdom
4 shared publicationsSarah Gleeson
Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith campus, Du Cane Road, London W12 0NN, United Kingdom
4 shared publications- Alexandra Cann
Department of infectious disease, Imperial College London, London, UK
2 shared publications Alison Cox
Department of Infection and Immunity Sciences, Northwest London Pathology NHS trust, Charing Cross Hospital, Fulham Palace Road, London W6 6RF, United Kingdom
2 shared publicationsAnjna Badhan
Department of infectious disease, Imperial College London, London, UK
2 shared publications
Latest Publications
- 15 March 2024
- Published by Cassyni
Haemodialysis Research
Leading young researchers describe their current patient-centred research from epidemiological, immunological and psychological perspectives Schedule:1. 13:30-14:00 Dialysis After Graft Loss - Survival Factors 2. 14:00-14:30 Dialysis After Graft Loss - Immune Injury 3. 14:30-15:00 Patient Related Outcomes with HaemodiafiltrationDialysis After Graft Loss - Survival FactorsKidney transplant failure contributes to a considerable proportion of new dialysis starters. In some centres there are dedicated clinics for patients with failing kidney transplants, however, the specific needs of patients with dialysis after graft loss (DAGL) may be lost in the non-specific clinical review practiced in the general dialysis community. This talk examines the mortality and morbidity risk in patients returning with DAGL. We will discuss the epidemiology of patients returning to dialysis after graft loss to identify areas of concern in management that warrant a more specialised approach.Dialysis After Graft Loss- Immune HarmAdvancements in clinical practices and improved management of chronic conditions have resulted in kidney transplant recipients living longer, which has caused a rise in patients returning to dialysis after graft failure and being waitlisted for re-transplantation. Additionally, there has been an increase in the use of deceased donor organs in transplantation. Most patients who return to dialysis after graft failure are taking at least one immunosuppression medication, which can lead to increased morbidity and mortality with prolonged use. However, balancing the risk of withdrawal of these medications with the risk of sensitisation for future transplantation is crucial. Therefore, patient selection and timing of relisting should be approached with an individualised and tailored approach to immunosuppression regimes.New Developments in Patient-Reported Outcomes with Results for Use in Person-Centered Kidney CareThe presentation will introduce how a current, structured, science-based patient-reported outcomes questionnaire look like, what its uses are, and how to recognize well-designed questionnaires beyond legacy instruments such as the KDQOL. Examples from recent studies such as the CONVINCE trial on hemodiafiltration will be presented showing new results that demonstrate their benefits in making treatment gaps and improvements visible from the perspective of the patient. There will also be an outlook into new developments of electronic patient-reported outcomes, including computer-adaptive testing using item-response theory that allows for interactive questionnaires that aim to reduce response burden and increase information content.
- 15 March 2024
- Published by Cassyni
Haemodialysis Research
Leading young researchers describe their current patient-centred research from epidemiological, immunological and psychological perspectives Schedule:1. 13:30-14:00 Dialysis After Graft Loss - Survival Factors 2. 14:00-14:30 Dialysis After Graft Loss - Immune Injury 3. 14:30-15:00 Patient Related Outcomes with HaemodiafiltrationDialysis After Graft Loss - Survival FactorsKidney transplant failure contributes to a considerable proportion of new dialysis starters. In some centres there are dedicated clinics for patients with failing kidney transplants, however, the specific needs of patients with dialysis after graft loss (DAGL) may be lost in the non-specific clinical review practiced in the general dialysis community. This talk examines the mortality and morbidity risk in patients returning with DAGL. We will discuss the epidemiology of patients returning to dialysis after graft loss to identify areas of concern in management that warrant a more specialised approach.Dialysis After Graft Loss- Immune HarmAdvancements in clinical practices and improved management of chronic conditions have resulted in kidney transplant recipients living longer, which has caused a rise in patients returning to dialysis after graft failure and being waitlisted for re-transplantation. Additionally, there has been an increase in the use of deceased donor organs in transplantation. Most patients who return to dialysis after graft failure are taking at least one immunosuppression medication, which can lead to increased morbidity and mortality with prolonged use. However, balancing the risk of withdrawal of these medications with the risk of sensitisation for future transplantation is crucial. Therefore, patient selection and timing of relisting should be approached with an individualised and tailored approach to immunosuppression regimes.New Developments in Patient-Reported Outcomes with Results for Use in Person-Centered Kidney CareThe presentation will introduce how a current, structured, science-based patient-reported outcomes questionnaire look like, what its uses are, and how to recognize well-designed questionnaires beyond legacy instruments such as the KDQOL. Examples from recent studies such as the CONVINCE trial on hemodiafiltration will be presented showing new results that demonstrate their benefits in making treatment gaps and improvements visible from the perspective of the patient. There will also be an outlook into new developments of electronic patient-reported outcomes, including computer-adaptive testing using item-response theory that allows for interactive questionnaires that aim to reduce response burden and increase information content.
- Open Access
- 10 September 2022
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 21, 100478
Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study
- 10 September 2022
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 21, 100478
Open AccessComparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study
- Open Access
- 9 September 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 53, 101642
Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients
- 9 September 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 53, 101642
Open AccessImmune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients
- Open Access
- 26 May 2022
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 6, 358
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study
Background: Lateral flow immunoassays (LFIAs) are able to achieve affordable, large scale antibody testing and provide rapid results without the support of central laboratories. As part of the development of the REACT programme extensive evaluation of LFIA performance was undertaken with individuals following natural infection. Here we assess the performance of the selected LFIA to detect antibody responses in individuals who have received at least one dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Methods: This was a prospective diagnostic accuracy study. Sampling was carried out at renal outpatient clinic and healthcare worker testing sites at Imperial College London NHS Trust. Two cohorts of patients were recruited; the first was a cohort of 108 renal transplant patients attending clinic following two doses of SARS-CoV-2 vaccine, the second cohort comprised 40 healthcare workers attending for first SARS-CoV-2 vaccination and subsequent follow up. During the participants visit, finger-prick blood samples were analysed on LFIA device, while paired venous sampling was sent for serological assessment of antibodies to the spike protein (anti-S) antibodies. Anti-S IgG was detected using the Abbott Architect SARS-CoV-2 IgG Quant II CMIA. A total of 186 paired samples were collected. The accuracy of Fortress LFIA in detecting IgG antibodies to SARS-CoV-2 compared to anti-spike protein detection on Abbott Assay Results: The LFIA had an estimated sensitivity of 92.0% (114/124; 95% confidence interval [CI] 85.7% to 96.1%) and specificity of 93.6% (58/62; 95% CI 84.3% to 98.2%) using the Abbott assay as reference standard (using the threshold for positivity of 7.10 BAU/ml) Conclusions: Fortress LFIA performs well in the detection of antibody responses for intended purpose of population level surveillance but does not meet criteria for individual testing.
- 26 May 2022
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 6, 358
Open AccessSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study
Background: Lateral flow immunoassays (LFIAs) are able to achieve affordable, large scale antibody testing and provide rapid results without the support of central laboratories. As part of the development of the REACT programme extensive evaluation of LFIA performance was undertaken with individuals following natural infection. Here we assess the performance of the selected LFIA to detect antibody responses in individuals who have received at least one dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Methods: This was a prospective diagnostic accuracy study. Sampling was carried out at renal outpatient clinic and healthcare worker testing sites at Imperial College London NHS Trust. Two cohorts of patients were recruited; the first was a cohort of 108 renal transplant patients attending clinic following two doses of SARS-CoV-2 vaccine, the second cohort comprised 40 healthcare workers attending for first SARS-CoV-2 vaccination and subsequent follow up. During the participants visit, finger-prick blood samples were analysed on LFIA device, while paired venous sampling was sent for serological assessment of antibodies to the spike protein (anti-S) antibodies. Anti-S IgG was detected using the Abbott Architect SARS-CoV-2 IgG Quant II CMIA. A total of 186 paired samples were collected. The accuracy of Fortress LFIA in detecting IgG antibodies to SARS-CoV-2 compared to anti-spike protein detection on Abbott Assay Results: The LFIA had an estimated sensitivity of 92.0% (114/124; 95% confidence interval [CI] 85.7% to 96.1%) and specificity of 93.6% (58/62; 95% CI 84.3% to 98.2%) using the Abbott assay as reference standard (using the threshold for positivity of 7.10 BAU/ml) Conclusions: Fortress LFIA performs well in the detection of antibody responses for intended purpose of population level surveillance but does not meet criteria for individual testing.
- Open Access
- 21 December 2021
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 6, 358
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study
Background: Lateral flow immunoassays (LFIAs) are able to achieve affordable, large scale antibody testing and provide rapid results without the support of central laboratories. As part of the development of the REACT programme extensive evaluation of LFIA performance was undertaken with individuals following natural infection. Here we assess the performance of the selected LFIA to detect antibody responses in individuals who have received at least one dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Methods: This was a prospective diagnostic accuracy study. Sampling was carried out at renal outpatient clinic and healthcare worker testing sites at Imperial College London NHS Trust. Two cohorts of patients were recruited; the first was a cohort of 108 renal transplant patients attending clinic following two doses of SARS-CoV-2 vaccine, the second cohort comprised 40 healthcare workers attending for first SARS-CoV-2 vaccination and subsequent follow up. During the participants visit, finger-prick blood samples were analysed on LFIA device, while paired venous sampling was sent for serological assessment of antibodies to the spike protein (anti-S) antibodies. Anti-S IgG was detected using the Abbott Architect SARS-CoV-2 IgG Quant II CMIA. A total of 186 paired samples were collected. The accuracy of Fortress LFIA in detecting IgG antibodies to SARS-CoV-2 compared to anti-spike protein detection on Abbott Assay Results: The LFIA had an estimated sensitivity of 92.0% (114/124; 95% confidence interval [CI] 85.7% to 96.1%) and specificity of 93.6% (58/62; 95% CI 84.3% to 98.2%) using the Abbott assay as reference standard (using the threshold for positivity of 7.10 BAU/ml) Conclusions: Fortress LFIA performs well in the detection of antibody responses for intended purpose of population level surveillance but does not meet criteria for individual testing.
- 21 December 2021
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 6, 358
Open AccessSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study
Background: Lateral flow immunoassays (LFIAs) are able to achieve affordable, large scale antibody testing and provide rapid results without the support of central laboratories. As part of the development of the REACT programme extensive evaluation of LFIA performance was undertaken with individuals following natural infection. Here we assess the performance of the selected LFIA to detect antibody responses in individuals who have received at least one dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Methods: This was a prospective diagnostic accuracy study. Sampling was carried out at renal outpatient clinic and healthcare worker testing sites at Imperial College London NHS Trust. Two cohorts of patients were recruited; the first was a cohort of 108 renal transplant patients attending clinic following two doses of SARS-CoV-2 vaccine, the second cohort comprised 40 healthcare workers attending for first SARS-CoV-2 vaccination and subsequent follow up. During the participants visit, finger-prick blood samples were analysed on LFIA device, while paired venous sampling was sent for serological assessment of antibodies to the spike protein (anti-S) antibodies. Anti-S IgG was detected using the Abbott Architect SARS-CoV-2 IgG Quant II CMIA. A total of 186 paired samples were collected. The accuracy of Fortress LFIA in detecting IgG antibodies to SARS-CoV-2 compared to anti-spike protein detection on Abbott Assay Results: The LFIA had an estimated sensitivity of 92.0% (114/124; 95% confidence interval [CI] 85.7% to 96.1%) and specificity of 93.6% (58/62; 95% CI 84.3% to 98.2%) using the Abbott assay as reference standard (using the threshold for positivity of 7.10 BAU/ml) Conclusions: Fortress LFIA performs well in the detection of antibody responses for intended purpose of population level surveillance but does not meet criteria for individual testing.